University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Jan. 25, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
Cepheid received Health Canada license for Xpert Xpress CoV-2/Flu/RSV plus
On Jan, 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
Australia Therapeutic Goods Administration granted provisional registration for Novavax COVID-19 vaccine
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
U.S. FDA authorizd InteliSwabï¾™ COVID-19 rapid tests for at-home testing for delta variant detection
On Jan. 13, 2022, OraSure Technologies that its InteliSwabï¾® COVID-19 rapid tests detected the Omicron variant as effectively…
South Korea Ministry of Food and Drug Safety approved Novavax COVID-19 vaccine
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
DoD awarded contract to Revival Health to purchase COVID-19 Antigen OTC kits in support of POTUS’ 500 million free at-home COVID-19 rests
On Jan. 7, 2022, the Department of Defense, in coordination with the U.S. Department of Health and Human…
Hologic added Aptima SARS-CoV-2 assay to its Global Access Initiative in resource-limited countries
On Jan 5, 2022, Hologic the addition of the Aptimaï¾® SARS-CoV-2 assay to its Global Access Initiative, a…
Revelar Biotherapeutics and Twist Bioscience announced RBT-0813 neutralized SARS-CoV-2 Omicron and Delta variants
On Jan 5, 2022, Revelar Biotherapeutics and Twist Bioscience announced that RBT-0813 binded to and neutralized the Omicron…
Pfizer provided U.S. Government with additional 10 million treatment courses of oral therapy to help combat COVID-19
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
Tonix Pharma announced exclusive collaboration with Kansas State University to develop LNP-Free mRNA vaccines
On Jan. 4, 2022, Tonix Pharmaceuticals announced an exclusive option agreement and research collaboration with Kansas State University…
U.S. DoD awarded $136.7 million to MilliporeSigma for domestic production capacity of COVID-19 point-of-care tests parts
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….
PacBio’s HiFiViral Surveillance Kit Performance not impacted by Omicron mutations
On Dec. 28, 2021, Pacific Biosciences announced that its new HiFiViral SARS-CoV-2 solution had successfully sequenced and captured…
Development of WRAI’s pan-coronavirus vaccine showed promise
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
Sorrento announced COVISTIX COVID-19 virus rapid antigen detection test detected the Omicron variant
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanï¾’s Ministry of Health, Labor and Welfare had…
Roche COVID-19 at-home test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
On Dec. 24, 2021, Roche announced that the U.S. Food and Drug Administration had granted Emergency Use Authorization…
Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
Cocrystal Pharma’s COVID-19 oral and intranasal/pulmonary protease inhibitors exhibited powerful in vitro potency against the SARS-CoV-2 Omicron variant
On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…
Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
USDA confirmed COVID-19 in a Canada lynx at a Pennsylvania zoo
On Dec. 21, 2021, the United States Department of Agricultureï¾’s National Veterinary Services Laboratories announced confirmation of SARS-CoV-2…
World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
European Commission granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
Oragenics extended collaboration with the National Research Council of Canada (NRC) to develop vaccine against Omicron variant
On Dec. 20, 2021, Oragenics announced it had extended a licensing and collaboration agreement with the National Research…
Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
Twist Bioscience began shipping synthetic RNA positive controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 variant for Development of Accurate Diagnostic Tests
On Dec. 15, 2021, Twist Bioscience announced that synthetic RNA positive controls were available for the SARS-CoV-2 Omicron…
Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
CEPI partnered with Affinivax to develop a novel COVID-19 vaccine to target variants
On Dec. 13, 2021, the Coalition for Epidemic Preparedness Innovations, and Affinivax announced a partnership to advance the…
Pfizer and BioNTech provided update on Omicron variant
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…